Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 43 - Drugs for specific purposes, not provided for in groups
Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317)
06/2002
06/13/2002WO2002046230A2 G-protein coupled receptors
06/13/2002WO2002046226A2 Trefoil factor 2 (tff2) peptides with moiety attached to asn15
06/13/2002WO2002046225A2 Use of sarp-1 for the treatment and/or prevention of scleroderma
06/13/2002WO2002046216A2 Human sprouty-4 polypeptide
06/13/2002WO2002046212A2 Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof
06/13/2002WO2002046197A1 Macroheterocylic compounds useful as kinase inhibitors
06/13/2002WO2002046194A2 Substituted imidazopyridines
06/13/2002WO2002046193A2 Heterocyclic ether substituted imidazoquinolines
06/13/2002WO2002046192A2 Thioether substituted imidazoquinolines
06/13/2002WO2002046191A2 Urea substituted imidazoquinoline ethers
06/13/2002WO2002046190A2 Sulfonamido ether substituted imidazoquinolines
06/13/2002WO2002046189A2 Aryl ether substituted imidazoquinolines
06/13/2002WO2002046188A2 Amido ether substituted imidazoquinolines
06/13/2002WO2002046186A1 Substituted thiazole derivatives bearing 3-pyridyl groups, process for preparing the same and use thereof
06/13/2002WO2002046184A1 Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases
06/13/2002WO2002046183A2 Indazolyl-substituted pyrroline compounds as kinase inhibitors
06/13/2002WO2002046182A1 Semicarbazides and their uses as cyclin dependent kinase inhibitors
06/13/2002WO2002046181A2 Abca-1 elevating compounds against coronary artery disease or atherosclerosis
06/13/2002WO2002046180A1 Klainetin and derivatives thereof, method for their production and the use of the same
06/13/2002WO2002046178A2 Benzofuran and benzothiophene derivatives as selective cox-2 inhibitors
06/13/2002WO2002046176A1 Ppar (peroxisome proliferator activated receptor) activators
06/13/2002WO2002046172A2 Substituted 1, 3, 5-triazines and pyrimidines as abca-1 elevating compounds against coronary artery disease or atherosclerosis
06/13/2002WO2002046171A2 Anilinopyrimidine derivatives as ikk inhibitors and compositions and methods related thereto
06/13/2002WO2002046169A1 Substituted 2-anilino-benzimidazoles and the use thereof as nhe-inhibitors
06/13/2002WO2002046167A1 Benzyl (idene)-lactams and their use as 5ht1-receptor ligands
06/13/2002WO2002046166A1 Phenylethenyl or phenylethinyl derivatives as glutamate receptor antagonists
06/13/2002WO2002046162A1 Ortho-substituted nitrogen-containing bisaryl compounds used as potassium channel inhibitors
06/13/2002WO2002046159A1 Guanidine and amidine derivatives as factor xa inhibitors
06/13/2002WO2002046154A1 Peroxisome proliferator activated receptor d activators
06/13/2002WO2002046148A1 Substituted anthranilic acids
06/13/2002WO2002046146A1 Substituted carboxylic acid derivatives
06/13/2002WO2002046144A1 Tetralone derivatives as antitumor agents
06/13/2002WO2002046141A2 Coumpounds of the formula r1-x-y-z-nr2r3 as abca-1 elevating agents against coronary artery disease or atherosclerosis
06/13/2002WO2002046134A1 Novel estrogen receptor ligands and methods iii
06/13/2002WO2002045867A1 Method for producing a partial or complete active ingredient coating on and in implants and onplants
06/13/2002WO2002045749A2 Methods for stimulating nervous system regeneration and repair by inhibition phosphodiesterase type 4
06/13/2002WO2002045740A1 Compositions containing gangliosides for use in the treatment of skin disorders
06/13/2002WO2002045737A2 Methods of treatment involving human mda-7
06/13/2002WO2002045734A1 Tahitian noni juice on cox-1 and cox-2 and tahitian noni juice as a selective cox-2 inhibitor
06/13/2002WO2002045730A1 Antimonocytic activity of extracts of piper betel leaves
06/13/2002WO2002045728A1 Cosmetic and/or dermopharmaceutical preparations containing leaf extracts of the plant argania spinosa
06/13/2002WO2002045719A1 Remedies for hibernation-like symptom and agents inducing or relieving hibernation-like symptom
06/13/2002WO2002045716A1 Use of pyrazolo[4,3-d]pyrimidines
06/13/2002WO2002045715A1 Nootropic effect enhancer
06/13/2002WO2002045710A1 Methods for treating neuropsychiatric disorders with nmda receptor antagonists
06/13/2002WO2002045705A2 Regenaration of blood vessels
06/13/2002WO2002045704A2 Prevention and treatment of tachyphylactic response
06/13/2002WO2002045686A2 Pharmaceutical paste comprising an acid-labile active ingredient
06/13/2002WO2002045652A2 Tyrosine kinase inhibitors
06/13/2002WO2002028842A3 Diazacycloalkanedione derivatives which are useful as lfa-1 antagonist
06/13/2002WO2002028825A3 Aminopyridinyl-, aminoguanidinyl- and alkoxyguanidinyl- substituted phenyl acetamides as protease inhibitors
06/13/2002WO2002026929A3 Kini-3 motor protein and methods for its use
06/13/2002WO2002024701A3 Substituted azepino[4,5b)indole derivatives
06/13/2002WO2002024700A3 SUBSTITUTED AZEPINO[4,5b]INDOLINE DERIVATIVES
06/13/2002WO2002024686A3 Farnesyl transferase inhibiting 6-heterocyclylmethyl quinoline and quinazoline derivatives
06/13/2002WO2002020011A3 A method for treating allergies using substituted pyrazoles
06/13/2002WO2002019967A3 Substituted hydrazine derivatives
06/13/2002WO2002018353A3 Oxazolidinone chemotherapeutic agents
06/13/2002WO2002017948A3 Control of crop pests and animal parasites through direct neuronal uptake
06/13/2002WO2002017857A3 Methods and compositions for inhibiting angiogenesis
06/13/2002WO2002015891A3 Pharmaceutical combination of angiotensin ii antagonists and ace inhibitors
06/13/2002WO2002014357A3 Use of gadd34 or pcna polypeptides in the treatment of cerebral ischaemic damage
06/13/2002WO2002014315A3 Substituted pyrazoles
06/13/2002WO2002012339A3 Sequences for integrin alpha-8
06/13/2002WO2002012245A3 Azabicyclic derivatives and their therapeutic use
06/13/2002WO2002008219A3 2-adamantylethylamines and their use in the treatment of conditions generally associated with abnormalities in glutamatergic transmission
06/13/2002WO2002006286A3 IMIDAZO[1,2-a]PYRAZINES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS
06/13/2002WO2002003962A3 Drug delivery system for poorly water soluble drugs
06/13/2002WO2001098350A3 Compositions comprising net-4 modulations and their use for treating neoplastic disease
06/13/2002WO2001098277A3 Substituted bicyclic derivatives for the treatment of abnormal cell growth
06/13/2002WO2001096330A3 Thrombin receptor antagonists
06/13/2002WO2001095884A3 Liposomal benzoquinazoline thymidylate synthase inhibitor formulations
06/13/2002WO2001092294A3 Therapeutic anti-melanoma compounds
06/13/2002WO2001090159A3 Compositions and methods for delivery of a molecule into a cell
06/13/2002WO2001090104A3 -(pyrrolidin-1-ylmethyl)-3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives and their use as modulators of protein kinases
06/13/2002WO2001089554A3 Treatment of acute coronary syndrome with glp-1
06/13/2002WO2001087981A3 Human monoclonal antibody against a costimulatory signal transduction molecule ailim and pharmaceutical use thereof
06/13/2002WO2001085257A3 Opioid antagonist compositions and dosage forms
06/13/2002WO2001085145A3 A pharmaceutical composition and method of treatment of diseases of cognitive dysfunction in a mammal
06/13/2002WO2001083438A3 New gamma selective retinoids
06/13/2002WO2001079198B1 Pyrazoles for inhibiting protein kinase
06/13/2002WO2001079170A3 Aminophenoxyacetamide derivatives and pharmaceutical composition containing thereof
06/13/2002WO2001077057A3 Halogenated triphenylethylene derivatives as selective estrogen receptor modulators
06/13/2002WO2001074844A3 Selective linear peptides with melanocortin-4 receptor (mc4-r) agonist activity
06/13/2002WO2001072721A3 Synergistic methods and compositions for treating cancer
06/13/2002WO2001070233A3 Apoptosis inhibiting composition comprising a 15-keto-prostaglandin or derivative thereof
06/13/2002WO2001059103A3 Method and reagent for the modulation and diagnosis of cd20 and nogo gene expression
06/13/2002WO2001057242A3 Methods of protein destabilization and uses thereof
06/13/2002WO2001042461A3 Apoptin-associating protein
06/13/2002WO2001037819A3 Use of indirubine derivatives for making medicines
06/13/2002WO2001010444A3 A method of effecting phosphorylation in eucaryotic cells using thiamine triphosphate
06/13/2002WO2000037022A3 Combination therapy for the treatment of sepsis
06/13/2002WO1999059957A9 Compounds having reversible inhibiting activity of carnitine palmitoyl-transferase
06/13/2002US20020072631 2-amino-2-alkyl-3 hexenoic and hexynoic acid derivatives useful as nitric oxide synthase inhibitors
06/13/2002US20020072630 Therapy
06/13/2002US20020072615 Useful as intermediate in the preparation of certain small molecules that are useful in therapy or prophylaxis of inflammatory and immune cell-mediated disease
06/13/2002US20020072614 For therapy of cardiovascular, cerebrovascular, respiratory and renal disorders
06/13/2002US20020072610 Useful as an intermediate in the preparation of certain small molecules that are useful in therapy or prophylaxis of inflammatory and immune cell-mediated diseases
06/13/2002US20020072604 For prophylaxis and therapy of obesity, diabetes, sexual disorders, eating disorder; for modulating appetite and metabolic rates; for stimulating appetite of livestock for treatment of ketosis, postpartum anestrus
06/13/2002US20020072540 For therapy, prophylaxis and diagnosis of respiratory distress syndrome or other pulmonary diseases that are associated with deficiency of lung surfactant
1 ... 929 930 931 932 933 934 935 936 937 938 939 940 941 942 943 944 945 946 947 948 949 ... 1564